New drug KK2223 enters early human testing for Tough-to-Treat T-Cell lymphoma
Disease control
Not yet recruiting
This early-stage trial is testing an experimental drug called KK2223 in 72 adults with T-cell lymphoma (a type of blood cancer) that has returned or not responded to prior treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processe…
Phase: PHASE1 • Sponsor: Kyowa Kirin, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC